Novelglue Novelglue

Novelglue

Bio-adhesive engineered for wet environments

Novelglue is a functional adhesive protein built on a recombinant mussel foot protein. It delivers 63 kPa wet tensile strength and supports a cassette architecture for swapping in functional domains.

See the product Technology

Three Differentiators

A position
no other
product holds.

Animal-free, EGF active, and wet-adhesive. No competitor combines all three.

01

Animal-free recombinant technology

Unlike Matrigel™ (mouse EHS sarcoma) or CellTak™ (natural mussel extract), Novelglue is produced by recombinant expression, delivering consistent lot-to-lot quality.

02

Cassette adhesive technology

The FP2 domain is designed as a swappable cassette: EGF, growth factors, targeting peptides and other functional domains can be fused in to derive diverse products from a single platform.

03

High wet-environment adhesion

Delivers 63 kPa tensile strength under wet conditions — roughly 30× fibrin glue.

Who We Serve

Who we serve,
and what with.

Products from one platform each serve a different customer with different buying criteria. For each of four segments we organize the data that drives the decision.

Customer & partner data

  • NovelMatrix

    Regenerative medicine & cell therapy

    Animal-free, GMP-ready, lot reproducibility

  • NovelGlue

    Orthopedic / dental surgeons & makers

    63 kPa wet, no exotherm, spares bone regeneration

  • NovelDDS

    Pharma formulation & DDS teams

    24 h mucosal residence, EGFR targeting

  • Company

    Investors & BD partners

    3 markets, peer review, AMED validation

Market Opportunity

Multiple
growing
markets.

Global demand for animal-free materials and improved bioavailability continues to grow.

  • Cell culture substrates

    $17B $27.6B

    2032 / CAGR 7.0%

    Source: Stats Market Research (2024)

  • Bone & dental cement

    $1.2–3.1B $1.6–4.3B

    2030 / CAGR 5.4–6.5%

    Source: Mordor / Grand View / M&M (2024–25)

  • Bone putty

    $0.9B $1.35B

    2030 / CAGR 6.0%

    Source: Bone void filler reports (2024)

  • Drug delivery

    $1,888B $3,496B

    2032 / CAGR 8.0%

    Source: Data Bridge Market Research (2024)

  • 63 kPa
    Wet tensile strength
  • 30×
    vs. fibrin glue
  • AMED
    Translational research grant (H/A)
  • PCT
    JP filed / PCT filed

Third-party Validation

AMED
translational
research & more

Selected for AMED translational research seed H (2025–26, Kyoto Univ.) and seed A (2025–26, Hokkaido Univ.), among other independent grants and awards — third-party validation of the technology.

Awards & Grants

  1. 2025–26 Grant AMED translational research seed H (Kyoto Univ.)
  2. 2025–26 Grant AMED translational research seed A (Hokkaido Univ.)
  3. 2025 Award Toyo Keizai – Top 100 Promising Ventures
  4. 2023 Award HVC KYOTO 2023 – Kansai Innovation Initiative Award
  5. 2020 Grant Ikeda Senshu Bank Innovation R&D Grant 2020
  6. 2020 Grant Shiga Tech Planter Prototype Support 2020
  7. 2019 Grant Kansai Mirai Joint Research Grant 2019
  8. 2019 Award Brave 2019 – Uchida & Samejima Law Office Prize
  9. 2018 Grant NEDO Research and Development-Type Venture Support 2018
  10. 2017 Award Shiga Tech Planter 2017 (Takara Bio Award, Kansai Urban Bank Award) and MarineTech Grand Prix 2017 (DNP Award)

Collaborate,
license,
partner.

We welcome inquiries from pharmaceutical and medical device companies, regenerative medicine researchers, and investors.

Contact us Technology